期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

脂溶性铂复合物抗癌药——Miriplatin Hydrate 被引量：2

原文传递
导出
摘要 Miriplatin Hydrate是大日本住友制药株式会社开发的脂溶性铂复合物抗癌药,商品名：Miripla,化学名：（SP-4-2）-[（1R,2R）-1,2环己二氨-N,N′]二（十四酸-O）合铂,CAS登记号：141977-79-9,结构式见图1,分子式C34H68N2O4Pt·H2O，相对分子质量：782．01。用于肝细胞癌，将70mg本品溶于3．5mL本品专用混悬液中，
作者 王利华 赵丽嘉 陈常青
机构地区 天津医药集团太平医药有限公司 天津药物研究院信息中心
出处 《药物评价研究》 CAS 2010年第4期323-326,共4页 Drug Evaluation Research
关键词 MIRIPLATIN HYDRATE 脂溶性铂复合物抗癌药 肝细胞癌
分类号 R979.1 [医药卫生—药品]
  • 相关文献

参考文献9

  • 1Mitsuharu Hanada,Akemi Baba,Yasuyuki Tsutsumishita,Toshihiro Noguchi,Takashi Yamaoka,Nobuyoshi Chiba,Fumio Nishikaku.Intra-hepatic arterial administration with miriplatin suspended in an oily lymphographic agent inhibits the growth of tumors implanted in rat livers by inducing platinum-DNA adducts to form and massive apoptosis[J]. Cancer Chemotherapy and Pharmacology . 2009 (3)
  • 2Takuji Okusaka,Shuichi Okada,Toshio Nakanishi,Shigetoshi Fujiyama,Yasuhiko Kubo.Phase II Trial of Intra-Arterial Chemotherapy using a Novel Lipophilic Platinum Derivative (SM-11355) in Patients with Hepatocellular Carcinoma[J]. Investigational New Drugs . 2004 (2)
  • 3Kenji Ikeda,Satoshi Saitoh,Masahiro Kobayashi,Yoshiyuki Suzuki,Fumitaka Suzuki,Akihito Tsubota,Yasuji Arase,Kazuaki Chayama,Naoya Murashima,Hiromitsu Kumada.Hepatic vascular side effects of styrene maleic acid neocarzinostatin in the treatment of hepatocellular carcinoma[J]. Journal of Gastroenterology . 2000 (5)
  • 4Sakaguchi T,Yoshimatsu S,Sagara K,et al.Intra-arterial infusion of SMANCS for treatment of patientswith hepatocellular carcinoma-adverse reactions andcomp-lications. Gan To Kagaku Ryono . 1998
  • 5Hanada,M,Baba A,Tsutsumishita Y,et al.Intra-hepatic arterial administration with miriplatin suspended in an oily lymphographic agent inhibits the growth of human hepatoma cells orthotopically implanted innude rats. Cancer Science . 2009
  • 6Okusaka,T,Okada,S,Ishii,H,Ikeda,M,Nakasuka,H,Nagahama,H,Iwata,R,Furukawa,H,Takayasu,K,Nakanishi,Y,Sakamoto,M,Hirohashi,S,Yoshimori,M.Transarterial chemotherapy with zinostatin stimalamer for hepatocellular carcinoma. Oncology . 1998
  • 7Maeda,M,Uchida,NA,Sasaki,T.Liposoluble platinum(II) complexes with antitumor activity. Japanese Journal of Cancer Research . 1986
  • 8Kishimoto,S,Noguchi,T,Yamaoka,T,Fukushima,S,Takeuchi,Y.Antitumor effects of a novel lipophilic platinum complex (SM-11355) against a slowly-growing rat hepatic tumor after intra-hepatic arterial administration. Biological and Pharmaceutical Bulletin . 2000
  • 9FUJIYAMA S,SHIBATA J,MAEDA S,et al.Phase I clinical study of a novel lipophilic platinum complex (SM-11355) in pa- tients with hepatocellular carcinoma refractory to cisplatin/lipi- odol. British Journal of Cancer . 2003

同被引文献21

  • 1李桂杰,周祝谦,王连祥.经肝动脉化疗栓塞术[J].山东医药,2006,46(17):87-88. 被引量：2
  • 2IMAI Y, CHIKAYAMA T, NAKAZAWA M, et al. Usefulness of miriplatin as an antieaneer agent for transcatheter arterial chemo- embolization in patients with unresectable hepatocellular carcino- rna[J]. J Gastroenterol, 2012,47(2) : 179 -186.
  • 3KISHIMOTO S, NOGUCHI T, YAMAOKA T, et al. Antitumor effects of a novel lipophilic platinum complex (SM-11355) a- gainst a slowly-growing rat hepatictumor after intra-hepatic arterial administration [ J]. Biol Pharm Bull,2000, 23 (3) : 344 - 348.
  • 4HANADA M, BABA A, TSUTSUMISHITA Y, et al. Intra-he- patic arterial administration with miriplatin suspended in an oily lymphographic agent inhibits the growth of human hepatoma cells orthotopically implanted innude rats [ J].. Cancer Sci, 2009, 100 (1) : 189 -194.
  • 5HANADA M, BABA A; TSUTSUMISHITA Y, et al. Intra-he- patic arterial administration with miriplatin suspendedin an oily lymphographic agent inhibits the growth of tumors implanted in rat livers by inducing platinum-DNA adducts to form and massive ap- optosis [ J ]. Cancer Chemother Pharmacol, 2009, 64 (3) : 473 - 483.
  • 6FUJIYAMA S, SHIBATA J, MAEDA S, et al. Phase I clinical study of a novel lipophilic platinum complex (SM-11355) in pa- tients with hepatocellular carcinomarefractory to cisplatin/lipiodol [J]. Br J Cancer, 2003, 89(9) : 1614 -1619.
  • 7OKUSAKA T, OKADA S, NAKANISHI T, et al. Phase II trial of intra-arterial chemotherapy using a novellipophilic platinum de- rivative ( SM-11355 ) in patients with hepatocellular carcinoma [ J ]. Invesi New Drugs, 2004, 22 (2) : 169 - 176.
  • 8OKABE K, BEPPU T, HARAOKA K,et al. Safety and short- term therapeutic effects of miriplatin-lipiodol suspension in transarterial chemoembolization (TACE) for hepatocellular carci- noma [ J ]. Anticancer Res, 2011,31 ( 9 ) : 2983 - 2988.
  • 9IMAI N, 1KEDA K, SEKO Y, et al. Previous chemoembolization response after transcatheter arterial chemoembolization (TACE) can predict the anti-tumor effect of subsequent TACE with miripl- atin in patients with recurrent hepatocellular carcinoma[ J ]. On- cology,2011,80(3 -4) :188 - 194.
  • 10董家鸿,吕文平.肝细胞癌治疗的理念与技术进展[J].中华临床医师杂志（电子版）,2008,2(2):1-3. 被引量：14

引证文献2

二级引证文献9

药物评价研究
2010年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部